title: [Global challenges of Haemophilus vaccinations quarter of a century after the Hib project].
abstract: Global challenges of Haemophilus vaccinations quarter of a century after the Hib project In 2000, 8.13 million children contracted invasive Haemophilus infection globally, 0.37 million of which died. These were unnecessary disease cases and deaths that would have been preventable with the Hib vaccine. The vaccine was developed during the 1980's. During its application for more than twenty years, the vaccine has proven to be effective, safe and cost-effective. The wide application of the Hib vaccine has led to the eradication of life-threatening Haemophilus diseases from the industrialized countries, whereas in developing countries the vaccine should be permanently included in national vaccination programs.
authors.affiliation: Terveyden ja hyvinvoinnin laitos, PL 30 00271 Helsinki.
authors.forename: Juhani
authors.initials: J
authors.lastname: Eskola
authors.forename: Steven
authors.initials: S
authors.lastname: Black
mesh_terms: D016667:Bacterial Capsules / Q000276:immunology*; D002648:Child; D014943:Global Health; D006192:Haemophilus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000276:immunology*; D006801:Humans
chemical_list: D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine